TransCode Therapeutics (NASDAQ:RNAZ) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note released on Thursday, Benzinga reports. The firm currently has a $3.00 price target on the stock.

TransCode Therapeutics Stock Performance

Shares of RNAZ stock traded up $0.00 during trading on Thursday, reaching $0.25. 307,138 shares of the company’s stock traded hands, compared to its average volume of 1,068,310. The firm’s 50-day moving average is $0.73 and its 200 day moving average is $0.78. TransCode Therapeutics has a 1 year low of $0.22 and a 1 year high of $128.00.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its earnings results on Wednesday, May 15th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.05. On average, sell-side analysts anticipate that TransCode Therapeutics will post -1.98 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC acquired a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned about 0.84% of TransCode Therapeutics as of its most recent filing with the Securities and Exchange Commission.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.